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Objective: Although previous studies have included early reexploration for 
bleeding as a risk factor in analyzing adverse outcomes after cardiac opera- 
tions, reexploration for bleeding has not been systematically examined as a 
multivariate risk factor for increased morbidity and mortality after cardiac 
surgery. Furthermore, multivariate predictors of the need for reexploration 
have not been identified. Accordingly, we performed a retrospective analysis of 
6100 patients requiring cardiopulmonary bypass from January 1, 1986, to 
December 31, 1993. Methods: Eighty-five patients who had ventricular assist 
devices were excluded from further analysis because of the prevalence of bleed- 
ing and the significant morbidity and mortality associated with placement of a 
ventricular assist device, unrelated to reexploration. In the remaining 6015 
patients, potential adverse outcomes analyzed included operative mortality, 
mediastinitis, stroke, renal failure, adult respiratory distress syndrome, pro- 
longed mechanical ventilation, sepsis, atrial arrhythmias, and ventricular 
arrhythmias. To control for the confounding effects of other risk factors, we 
performed a multivariate logistic regression analysis. Potential covariates 
considered in the logistic model included age, sex, race, history of reoperation, 
urgency of the operation, congestive heart failure, prior myocardial infarction, 
renal failure, diabetes, hypertension, chronic obstructive pulmonary disease or 
stroke, and the bypass and crossclamp time. Results: The overall incidence of 
reexploration was 4.2% (253/6015). Four independent risk factors--increased 
patient age (p < 0.001), preoperative r nal insufficiency (p = 0.02), operation 
other than coronary bypass (p < 0.001), and prolonged bypass time (p = 
0.03)--were identified as predictors of the need for reexploration. The preop- 
erative use of aspirin, heparin, or thrombolytic agents and the bleeding time 
were not identified as predictors. Reexploration for bleeding was identified as 
a strong independent risk factor for operative mortality (p = 0.005), renal 
failure (p < 0.0001), prolonged mechanical ventilation (p < 0.0001), adult 
respiratory distress syndrome (p = 0.03), sepsis (p < 0.0001), and atrial 
arrhythmias (p = 0.006). Conclusion: These data indicate that meticulous 
attention to surgical hemostasis and possibly application of recently developed 
modalities designed to facilitate perioperative correction of coagulopathy could 
improve outcomes after cardiac operations. (J Thorac Cardiovasc Surg 1996; 
111:1037-46) 
M any studies have examined the application of perioperative measures designed to reduce 
bleeding, 1 but only a single recent study has com- 
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pared the outcome of patients who required re- 
exploration with that of patients who did not. 2 
Applying stepwise multivariate logistic regression, 
Unsworth-White and associates 2 found early reex- 
ploration for bleeding to be an independent risk 
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factor for operative mortality, prolonged intensive care 
unit (ICU) stay, and the need for an intraaortlc 
balloon pump. Although prior studies have found 
early reexploration for bleeding to be an independent 
multivariate risk factor for specific adverse outcomes 
after cardiac operations for such conditions as atrial 
fibrillation 3 and deep sternal wound infection, 4 no 
study has focused on both the risk factors for and the 
consequences of early reexploration for bleeding. 
Recent clinical trials have demonstrated the effi- 
cacy of aprotinin 1 or desmopressin acetate 5 for 
reducing the amount of postoperative bleeding. 
However, these trials were not large enough to 
demonstrate conclusively a reduction in periopera- 
tive morbidity or mortality. In contrast, retrospec- 
tive analysis of a large group of patients undergoing 
procedures requiring cardiopulmonary bypass 
(CPB) might identify the consequences of postop- 
erative bleeding and, therefore, may indirectly pro- 
vide the basis for further clinical trials. If the 
consequences of reexploration and excessive bleed- 
ing were minimal, then these agents would not be 
likely to have an important impact; conversely, if the 
consequences were significant, these agents may 
substantially reduce morbidity and mortality. 
The objective of the present study was to assess 
the significance of early reexploration for bleeding 
on morbidity and mortality after cardiac operations. 
Additionally, we sought to identify patients at high 
risk for perioperative bleeding and reexploration to 
aid in treatment strategies designed to reduce bleed- 
ing and the attendant risks of transfusion. Specifi- 
cally, using multivariate logistic regression, we ex- 
amined the effects of early reexploration on 
operative mortality, mediastinitis, troke, renal fail- 
ure, adult respiratory distress syndrome (ARDS), 
prolonged mechanical ventilation, sepsis, atrial ar- 
rhythmias, and ventricular arrhythmias. Addition- 
ally, we used logistic regression to screen for preop- 
erative and intraoperative risk factors for early 
reexploration for bleeding. 
Methods 
Between January 1, 1986, and December 31, 1993, a 
total of 6100 patients underwent cardiac surgical proce- 
dures necessitating CPB at Barnes Hospital, Washington 
University Medical Center, St. Louis. In conjunction with 
cardiac surgery, 85 patients underwent placement of a 
ventricular assist device and were excluded from further 
analysis because of the prevalence of bleeding and the 
high rate of mortality and morbidity in this patient 
population, unrelated to reexploration. Characteristics of
the study group are listed in Table I. 
Demographic data regarding each patient were ob- 
tained retrospectively from the patient's chart before 
hospital discharge and were entered into a computer 
database. Pertinent information for the current study 
included the patient's age, sex, race, urgency of the 
procedure, and preoperative medical history including a 
history of previous cardiac operation, myocardial infarc- 
tion, congestive heart failure, New York Heart Associa- 
tion functional class, diabetes, chronic obstructive pulmo- 
nary disease, renal insufficiency, and peripheral vascular 
disease. A history of bleeding disorder was sought from all 
patients and the preoperative use of aspirin, heparin, or 
thrombolytic agents was recorded. A bleeding time was 
obtained for 4272 of the patients (71%). Recorded oper- 
ative details included the CPB time, aortic crossclamp 
time, the number and type of distal bypasses, and use of a 
ventricular assist device or an intraaortic balloon pump. 
Postoperative details that were recorded included the 
need for early reexploration for bleeding, defined as the 
need for resternotomy within 24 hours of the first opera- 
tive procedure, amount of postoperative bleeding, and 
amount of blood products required. Recorded outcomes 
were the operative mortality defined as an in-hospital 
death, postoperative myocardial infarction, pulmonary 
embolus, renal failure, prolonged mechanical ventilation, 
cerebrovascular ccident, atrial and ventricular arrhyth- 
mias, deep sternal wound infection, superficial sternal 
wound infection, and saphenous vein harvest site (leg) 
infection. Postoperative myocardial infarction was defined 
by clinical criteria and electrocardiographic changes or 
characteristic serum enzyme levations (creatine kinase, 
lactic dehydrogenase). 
The decision to return to the operating room for an 
adult of average weight was made by the responsible 
surgeon and was based on conventional guidelines6: (1) 
drainage of more than 500 ml in the first hour, total 
drainage of more than 800 ml in the first 2 hours, 900 ml 
in the first 3 hours, or greater than 1000 ml in the first 4 
hours or 1200 ml in the first 5 hours; (2) sudden massive 
bleeding or cardiac tamponade. 
Operative procedures were performed by eleven differ- 
ent surgeons with a variety of cannUlation and cardiople- 
gia techniques. Myocardial protection was performed 
most commonly with antegrade cold crystalloid cardiople- 
gia; however, more recently there was a trend toward the 
use of antegrade or retrograde (cold or warm) blood 
cardioplegia. 
The anticoagulation a d reversal protocol for the first 6 
years of the study (1986 to 1992) included an initial fixed 
dose of heparin (250 units/kg) and additional boluses of 
5000 units of heparin when the activated clotting time fell 
below 480 seconds during the CPB run. Heparin was 
neutralized with a fixed dose of protamine (0.8 mg prota- 
mine per milligram total heparin dose). For the interval 
from 1992 to i993, a new protocol was established on the 
basis of the results of a prospective, randomized trial. 7 An 
initial dose of heparin was based on an automated heparin 
dose-response assay. Additional heparin doses were ad- 
ministered if the lleparin concentration was less than the 
reference concentration or for an activated clotting time 
less than 480 seconds. The protamine dose was based on 
the initial heparin concentration. 
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Table I. Preoperative patient characteristics 
Characteristic Reexploration* (n = 253) No reexploration Oz = 5762) p Value? 
Age (yr) 63.4 _+ 13.2 61.5 -+ 13.2 
Male (sex) (%) 61.9 652 
White (race) (%) 77.1 78.8 
Procedure (%CABG) 54.8 69.2 
NYHA class (mean) 1.1 _+ 1.1 1.6 _+ 1.0 
Range (I-IV) 
Previous MI (mean No.) 0.73 -+ 0.90 0.74 -+ 0.88 
Urgent/emergency operation 32.1 23.9 
Previous cardiac operation 6.7 13.0 
History of preoperative aspirin use 43.2 46.6 
Bleeding time (min) 6.2 _+ 3.1 6.1 + 3.0 
History of bleeding 0.4 0.5 
Preoperative heparin use 32.5 29.7 
Preoperative thrombolytic use 3.2 4.6 
Preoperative history 
Diabetes mellitus 21.8 24.1 
Chronic renal insufficiency 15.9 9.5 
Preoperative dialysis 0.7 0.7 
Hypertension 56.1 55.2 
COPD 13.8 12.2 
Stroke 8.0 7.8 
LV ejection fraction:) 0.51 0.53 
Cardiac index (L- min -1 • m -z) 2,4 2.4 
CPB time (rain) 154.4 -- 77.3 124.6 _+ 53.8 
Aortic crossclamp time (min) 68.6 + 43.5 58.8 _+ 36.0 
p = 0.02 
p = 0.19 
p = 0.61 
p < 0.001 
p = 0.001 
p = 0.90 
p = 0 .007  
p = 0 .05  
p = 0.30 
p = 0.88 
p 1.0 
p = 0.32 
p = 0.30 
p = 0.37 
p < 0.0001 
p 0.93 
p = 0.79 
p = 0.39 
p 0.92 
p = 0.17 
p = 0.30 
p < 0.0001 
p < 0.0001 
NYHA, New York Heart Association; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; LV, left ventricular. 
*Reexploration group excludes patients with ventricular assist devices. 
tBinary variables were compared by means of Fisher's exact test and continuous variables were compared by means of an independent S udent's t test. 
Boldface type indicates that the p value is significant. 
~cData were available on only a subgroup of the entire patient group. 
Pharmacologic adjuncts for controlling microvascular 
bleeding including desmopressin acetate were adminis- 
tered in the setting of clinical bleeding when point-of-care 
hemostasis demonstrated the presence of platelet dys- 
function. Approximately 10% to 15% of the patients 
received esmopressin acetate. Aprotinin was used rarely 
because of concern about hypercoagulability and its ef- 
fects on graft patency. Aminocaproic acid (Amicar) was 
used for patients in whom the risk of bleeding was high, 
including those undergoing combined coronary artery 
bypass grafting (CABG) and valve operations or repair of 
thoracic aneurysms. 
Statistical nalysis was performed with SYSTAT for Win- 
dows (Statistics, version 5 edition, 1992, SYSTAT, Inc., 
Evanston, Ill.), and the multivariate logistic regression was 
performed with the LOGIT module from SYSTAT (Stein- 
berg, D and Colla, P. LOGIT: a supplementary module for 
SYSTAT, 1991). Descriptive data were given as mean _+ 
standard deviation and comparisons between continuous 
variables were performed with Student's t test. Categoric 
variables were compared with a X 2 test or Fisher's exact est 
as appropriate.  Mult ivar iate stepwise logistic regression was 
per formed in a negative fashion by including variables in the 
mode l  with ap  value 0.15 or less and excluding variables with 
ap  value greater  than  0.20 as recommended in Hosmer  and 
Lemeshow.  s In all cases, a p value of  0.05 or less was 
considered to be significant. 
Results 
The overall rate of reexploration was 4.2% (253/ 
6015). The rate of reexploration for patients under- 
going isolated primary or reoperative CABG was 
3.3% (134/4092). Patients undergoing reexploration 
for bleeding had a longer ICU stay (4.5 _+ 7.9 days 
versus 9.7 + 12.7 days; p < 0.0001) and a longer 
total hospital stay (13.1 +_ 14.6 days versus 20.5 _+ 
22.4 days; p < 0.0001) than patients not requiring 
reexploration. 
Patient characteristics. The group requiring 
early reexploration for Needing differed in several 
respects from the control group (see Table I). 
Specifically, the reexploration group was older (p = 
0.02), underwent a higher percentage of procedures 
other than CABG (p < 0.001), had a higher inci- 
dence of urgent or emergency operation (p = 
0.007), and contained more patients undergoing a
reoperation (p = 0.05). Additional differences in- 
cluded a higher prevalence of chronic renal insuffi- 
ciency not necessitating dialysis (p < 0.0001) and a 
longer CPB and aortic crossclamp time. Notably, the 
two groups did not differ in the preoperative use of 
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Table II. Multivariate logistic regression analysis of 
preoperative risk factors for early re-exploration for 
bleeding 
95% 
Odds Confidence 
Variable ratio interval p Value 
Age 1.01 1.00-1.02 p < 0.001 
Sex 1.1 0.9-1.5 p - 0.30 
Procedure 1.9 1.5-2.5 p < 0.001 
NYHA class 1.1 1.0-1.3 p = 0.09 
Urgent/emergency procedure 1.1 1.0-1.3 p = 0.14 
Reoperat ion 0.9 0.7-1.3 p - 0.70 
Renal  insufficiency 1.5 1.0-2.1 p = 0.02 
History of bleeding 0.7 0.1-5.4 p = 0.75 
Bleeding t ime 1.0 0.9-1.0 p = 0.36 
Aspir in use 0.9 0.7-1.1 p = 0.28 
Hepar in  1.0 0.8-1.3 p = 0.84 
Thrombolyt ic agents 0.6 0.2-1.5 p - 0.26 
Eject ion fraction 0.5 0.2-1.2 p = 0.12 
CPB t ime 1.003 1.0-1.005 p = 0.03 
Crossclamp t ime 0.996 0.99-1.001 p = 0.15 
NYHA, New York Heart Association. Boldface type indicates that the p 
value is significant. 
Table IlL Postoperative bleeding 
Chest tube No 
drainage Reexploration reexploration p Value 
Within 12 hr. (ml) 766 _+ 891 292 -+ 260 p < 0.0001 
Within 24 hr. (ml) 2088 _+ 1292 648 _+ 456 p < 0.0001 
aspirin (p = 0.30), the use of thrombolytic agents 
(p = 0.30) or heparin (p = 0.32), the preoperative 
bleeding time (p = 0.88), or in the preoperative 
history of a bleeding disorder (p = 1.0). 
Preoperative risk factors for early reexploration. 
The preoperative variables listed in Table I were 
entered into a multivariate logistic regression model 
to screen for risk factors leading to bleeding com- 
plications necessitating early reexploration. The re- 
sults of the decreasing stepwise logistic regression 
analysis are presented in Table II. Only four vari- 
ables-age (p < 0.001), preoperative renal insuffi- 
ciency (p = 0.02), procedure other than CABG (p < 
0.001), and prolonged CPB time (p = 0.03)-- 
emerged as independent multivariate predictors of 
the need for early reexploration. Notably, the pre- 
operative use of aspirin, heparin, or thrombolytic 
agents, the history of a bleeding disorder, and the 
bleeding time were not multivariate predictors of 
the need for early reexploration. 
Amount of postoperative bleeding and use of 
blood products. Patients requiring early reexplora- 
tion averaged 766 _+ 891 ml of mediastinal chest 
Table IV. Intraoperative and postoperative use of 
homologous blood products 
No 
Blood product Reexploration reexploration p Value 
Packed cells (intraop.) 
% Patients not 8.7 45.1 
requiring 
Mean No. of units 4.0 -+ 1.0 3.3 _+ 1.0 p < 0.0001 
Fresh frozen 
plasma (intraop.) 
% Patients not 29.2 67.7 
requiring 
Mean No. of units 3.3 -+ 1.1 2.8 _+ 1.0 p < 0.0001 
Packed cells (postop.) 
% Patients not 2.8 29.5 
requiring 
Mean No. of units 4.4 -+ 0.7 3.4 _+ 0.9 p < 0.0001 
Fresh frozen plasma 
(postop.) 
% Patients not 13.4 69.5 
requiring 
Mean No. of units 3.5 -+ 1.0 2.7 _+ 1.0 p < 0.0001 
tube drainage in the first 12 hours after the opera- 
tion compared with 292 _+ 260 ml in the control 
group (Table III). These patients averaged 2088 + 
1292 ml of mediastinal chest tube drainage in the 
first 24 hours after the operation compared with 
648 _+ 456 ml for the control group. The control 
group was more than five times more likely to avoid 
intraoperative homologous transfusion of packed 
red blood cells (45.1% to 8.7%) than the reexplora- 
tion group and more than ten times more likely to 
avoid postoperative homologous blood transfusion 
(29.5% to 2.8%) (Table IV). The patients who did 
require intraoperative transfusion in both groups 
averaged 4.0 _+ 1.0 units of packed red blood cells 
for the reexploration group versus 3.3 + 1.0 units for 
the control group (p < 0.0001). The postoperative 
transfusion requirement for those patients needing 
transfusion was 4.4 _+ 0.7 units for the reexploration 
group and 3.4 _+ 0.9 units for the control group (p < 
0.0001). Similarly, both intraoperative and postop- 
erative transfusion of fresh frozen plasma were 
more common in the reexploration group than in 
the control group (intraoperative: 67.7% to 29.2%; 
p < 0.0001; postoperative: 69.5% to 13.4%; p < 
0.0001) (Table IV). 
Reexploration as a risk factor for adverse out- 
comes. The preoperative variables listed in Table I 
were included with reexploration for bleeding in a 
multivariate stepwise logistic model for each adverse 
outcome. Reexploration was included as a forced 
factor and patients with ventricular assist devices 
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Table V. Reexploration as a multivariate risk factor for adverse outcomes 
Relationship of outcome to reexploration 
Reexploration No reexploration 
(n = 253) (n = 5762) 
Multivariate Odds 
Outcome (n = 6015) No. % No. % No. % p value* ratio 
Operative mortality 270 4.5 27 10.7 243 4.2 0.005 2.0 
Mediastinitis 58 1.0 6 2.4 52 0.9 0.256 1.8 
Stroke 120 2.0 9 3.6 111 1.9 0.288 1.5 
Renal failure 259 4.3 40 15.8 219 3.8 <0.0001 3.9 
ARDS 109 1.8 11 4.3 98 1.7 0.030 2.1 
Prolonged mechanical 555 9.2 62 24.5 493 8.6 <0.0001 3.1 
ventilation 
Sepsis 244 4.1 32 12.6 212 3.7 <0.0001 3.0 
Atrial arrhythmias 2011 33.4 111 43.9 1900 33.0 0.006 1.5 
Ventricular arrhythmias 324 5.4 21 8.3 303 5.3 0.153 1.4 
ARDS, Adult respiratory distress syndrome 
*A multivariate decreasing stepwise logistic regression model was developed with reexploration for bleeding as a forced factor. Patients with ventricular assist 
devices (n - 85) were excluded from the analysis. Boldface type indicates that the p value is significant. 
Table VI. Relationship between the amount of bleeding and outcomes stratified by reexploration 
Prolonged 
Operative death mechanical Atrial arrhythmias 
Amount of (%) Renal failure (%) Sepsis (%) ventilation (%) ARDS (%) (%) 
chest ube 
drainage in No No No No No No 
24 hr (ml) ReexpL Reexpl. Reexpl. ReexpL Reexpl. Reexpl. Reexpl. Reexpl. Reexpl. Reexpl. Reexpl. Reexpl. 
0-500 3.0 12.5 3.8 12.5 3.6 18.8" 8.4 25.0* 1.3 6.3* 33.1 37.5 
(n = 2467) 
501-1000 2.8 16.0" 2.7 24.0* 2.3 8.0 6.8 20.0* 1.4 8.0* 33.6 48.0 
(n = 2449) 
1001-1500 4.5 10.4 3.9 6.3* 3.9 6.3* 10.2 27.1" 2.2 6.3 35.1 37.9 
(n = 607) 
1501-2000 4.3 8.3 9.3 10.4 12.1 8.3 23.6 14.6 6.4 2.1 41.4 47.9 
(n - 188) 
2001-2500 12.1 2.3 9.1 9.1 9.1 11.4 30.3 29.6 6.1 6.8 51.5 50.0 
(n 77) 
>2500 10.0 12.5 10.0 12.5 20.0 16.1 20.0 19.6 15.0 0.06 35.0 33.9 
(n 76) 
ReexpL, Reexploration for bleeding; ARDS, adult respiratory distress syndrome. 
*p < 0.05 by Fisher's exact est. 
were excluded from the analysis. Reexploration was 
determined to be an independent multivariate pre- 
dictor of operative death (odds ratio: 2.0; 95% 
confidence interval: 1.2 to 3.1; p = 0.005), postop- 
erative renal failure (3.9; 2.6 to 5.9; p < 0.0001), 
ARDS (2.1; 1.1 to 4.2;p = 0.03), prolonged mechan- 
ical ventilation (3.1; 2.2 to 3.1; p < 0.0001), sepsis 
(3.0; 1.9 to 4.5; p < 0.0001), and atrial arrhythmias 
(1.5; 1.1 to 1.9; p = 0.006) (Table V). 
Is there a detectable difference in outcome for 
patients with similar amounts of bleeding, some of 
whom undergo reexploration and others of whom do 
not? Outcomes in which reexploration was signifi- 
cant were stratified by the amount of bleeding (chest 
tube drainage in 24 hours [milliliters]) and reex- 
ploration (Table VI). In general, as the amount of 
bleeding increased, the decision to reexplore did not 
affect outcome. 
Reexploration as a risk factor in a low-risk sub- 
group. All patients who were less than 70 years of 
age, in New York Heart Association class I, and who 
were undergoing elective CABG were classified as a 
low-risk subgroup (n = 2244). A multivariate step- 
wise logistic regression analysis was performed on 
this subset to examine reexploration as a risk factor 
for adverse outcomes (Table VII). In this low-risk 
subgroup, reexploration remained a strong multivar- 
iate risk factor for operative death (p = 0.03), renal 
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Table VII. Reexploration as a multivariate risk factor for adverse outcomes in a "low-risk" subgroup 
Relationship of outcome to reexploration 
Reexploration No reexploration 
Outcome (n = 62) (n = 2182) Multivariate Odds 
(n = 2244) No. % No. % No. % p value* ratio 
Operative mortality 30 1.3 3 4.8 27 1.2 0.03 4.4 
Renal failure 21 0.9 5 8.1 16 0.7 <0.0001 17.5 
ARDS 28 1.3 3 4.8 25 1.1 0.02 4.6 
Atrial arrhythmias 562 25.0 23 37.1 539 24.7 0.04 1.8 
ARDS, Adult respiratory distress yndrome. 
*A multwariate decreasing stepwise logistic regression model was developed for all patients who were less than 70 years of age, in New York Heart 
Association class l, undergoing elective CABG. Reexploration for bleeding was included as a forced factor Patients receiving ventricular assist devices (n = 
85) were excluded from the analysis. 
failure (p < 0.0001), ARDS (p = 0.02), and atrial 
arrhythmias (p = 0.04). 
Discussion 
The decision to reexplore for postoperative bleed- 
ing is frequently a reflexive one when bleeding is 
excessive in the face of normal coagulation param- 
eters, indicating a surgical cause for bleeding. How- 
ever, the decision may be more complicated in the 
setting of elevated coagulation parameters and 
moderately increased postoperative bleeding. Ac- 
cordingly, information about risk factors that may 
lead to reexploration and the consequences of early 
reexploration for postoperative h morrhage may be 
useful to the cardiac surgeon. If the consequences of 
reexploration and postoperative hemorrhage are 
significant, then attention to surgical hemostasis and 
measures designed to reduce bleeding would be 
important. Furthermore, this information may be 
useful in deciding which patients should undergo 
reexploration. Thus the purpose of this study was to 
identify preoperative risk factors that predispose to 
reexploration for bleeding and to examine the ef- 
fects of reexploration on postoperative outcomes. 
The overall rate of reexploration in this study 
was 4.2% and is similar to previously reported 
rates of 3% to 5%. 4, 9 Multivariate logistic regres- 
sion identified four preoperative and intraopera- 
tive variables that were predictive of the need for 
reexploration: age (p < 0.001), renal insufficiency 
(p = 0.02), procedure other than CABG (p < 
0.001), and CPB time (p = 0.03). Advanced age is 
frequently identified as a risk factor for adverse 
outcomes after cardiac surgery and may predis- 
pose to surgical causes of postoperative bleeding 
by alterations in the tissues, making them more 
friable. Alterations in the tissues may be coupled 
with increased calcification of the aorta and other 
blood vessels, complicating surgical attempts at 
cannulation and, later, hemostasis. Although pro- 
longed CPB time and increased age were identi- 
fied as risk factors for reexploration for bleeding, 
their multivariate odds ratios were low (1.01 and 
1.003, respectively). 
Renal insufficiency leads to abnormalities in 
platelet function 1° that appear to act synergistically 
with CPB to increase postoperative bleeding. CPB 
has widely known detrimental effects on platelet 
function, so that prolonged CPB time would be 
expected to lead to an increased rate of postopera- 
tive bleeding and reexploration. Patients older than 
70 years of age with chronic renal insufficiency and 
CPB times longer than 120 minutes undergoing 
procedures other than CABG had a reexploration 
rate of 9.9% (20/202), or three times the rate of 
patients without these risk factors (2.7%; 67/2475; 
p < 0.001). Woodman and Harker 11 have suggested 
that patients at high risk may benefit from the 
administration of hemostatic agents in the periop- 
erative period. Thus older patients with chronic 
renal insufficiency undergoing procedures other 
than CABG who may be expected to have a long 
CPB time may benefit from the administration of 
aprotinin or desmopressin acetate. Both of these 
adjuncts have been proven to reduce postoperative 
bleeding in selected patients in randomized con- 
trolled trials. 3' 12 Nevertheless, their use is not wide- 
spread in the United States because of real and 
perceived problems with intravascular coagula- 
tion, 13 clotting of bypass grafts, 14 and renal failure.15 
Given the high rate of reexploration i this subgroup 
of patients, however, and the adverse outcomes with 
reexploration for bleeding, these patients may ben- 
efit from modalities designed to improve perioper- 
ative hemostasis. Furthermore, because of their high 
risk of postoperative bleeding, this subgroup may 
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represent an ideal cohort on which to base further 
studies of "antibleeding therapy." 
Our study did not identify preoperative aspirin, 
heparin, or thrombolytic use, a prolonged bleeding 
time, or a history of bleeding disorder as multivari- 
ate risk factors. A few small prospective studies have 
identified an increased bleeding time or aspirin 
use 16 as a risk factor for increased postoperative 
bleeding. In our study, aspirin also increased the 
amount of postoperative bleeding (706 _+ 446 ml vs 
670 + 427 ml; p = 0.009); however, there was no 
significant difference in the rate of reexploration 
(p = 0.28). In fact, the odds ratios for all of the 
aforementioned variables were less than or equal to 
1.0 and the p values were not close to significance 
(see Table IV). It is possible that because of the 
perceived increased risk for patients with these risk 
factors, surgeons treating these patients took extra 
precautions to avoid bleeding complications. Never- 
theless, the fact that these risk factors were of such 
low significance in a multivariate analysis when 
compared with age, renal failure, procedures other 
than CABG, and CPB time indicates that they are 
not significant risk factors for early reexploration 
and adverse outcomes. 
Almost 30% of patients who did not undergo 
reexploration for bleeding avoided intraoperative or
postoperative homologous blood transfusion. In 
contrast, only 3% of patients who did undergo 
reexploration avoided homologous transfusion. Al- 
though blood supplies are now screened carefully 
for human immunodeficiency virus and hepatitis B, 
other viral agents are still undetectable and are 
highly transmissible. Consequently, avoidance of 
transfusion by reducing the amount of postoperative 
bleeding and the rate of reexploration is highly 
desirable and cost-effective. 
Although reexploration has been identified by 
other investigators as a risk factor for certain ad- 
verse outcomes such as increased risk of atrial 
arrhythmias 3 or deep sternal wound infection, 4 only 
a single recent study has systematically investigated 
reexploration as a multivariate risk factor. Un- 
sworth-White and associates 2 tudied 2221 patients 
retrospectively and identified reexploration for 
bleeding as a risk factor for operative mortality, 
increased rate of intraaortic balloon pump use, and 
prolonged ICU stay. Our results also identified 
reexploration as a risk factor for operative death, 
renal failure, ARDS, prolonged mechanical ventila- 
tion, sepsis, and atrial arrhythmias. We demon- 
strated an increased ICU and total hospital stay for 
patients undergoing reexploration for bleeding. With 
cardiac surgery coming under increasing financial scru- 
tiny, the addition of measures designed to improve 
hemostasis and attention to the patient group identi- 
fied in this study as being at high risk for bleeding may 
reduce costs as well as improve outcome. 
An important question that may bear on the 
decision to reexplore the operative field is whether 
the identified increase in morbidity and mortality in 
the reexploration group is due only to the large 
amount of bleeding or if outcomes vary with the 
decision to reexplore for any given amount of post- 
operative bleeding. Stated another way, is there a 
detectable difference in outcome for patients with 
the same amount of bleeding, some of whom un- 
dergo reexploration and others of whom do not? 
The results in Table VI demonstrate an increase in 
morbidity and mortality for the patients with a small 
amount of bleeding (up to 1000 ml) who undergo 
reexploration. However, these results likely reflect 
the fact that patients with a small amount of bleed- 
ing who undergo reexploration have had a signifi- 
cant bleeding-associated complication such as peri- 
cardial tamponade that would independently affect 
their outcomes. For patients with greater amounts 
of bleeding, the decision to reexplore yielded no 
significant difference in outcomes, although as the 
amount of bleeding increased, patients who under- 
went reexploration tended to fare better. These 
results imply that in a patient with increased post- 
operative bleeding, the decision to reexplore can be 
made with the knowledge that the outcome will not 
be worsened by the decision and may be improved. 
Once the decision to reexplore is entertained, the 
increased morbidity and mortality has already en- 
sued. 
Although reexploration for bleeding affects out- 
come for the entire population, its effects on mor- 
bidity and mortality are perhaps most pronounced 
in the "low-risk" subgroup: patients less that 70 
years of age, in New York Heart Association class I, 
and undergoing elective CABG. For this subgroup, 
the odds ratio for operative death is 4.4 times 
greater than for the group of patients who did not 
undergo reexploration (4.8% vs 1.2%; p = 0.03), 
their rate of renal failure was 17.5 times greater 
(8.1% vs 0.7%;p < 0.0001), their rate of ARDS was 
4.6 times greater (4.8% vs 1.1%;p = 0.02), and their 
rate of atrial arrhythmias was 1.8 times greater 
(37.1% vs 24.7%; p = 0.04). These results under- 
score the significance of reexploration as a risk 
factor and provide the basis for recommending 
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attainment of careful surgical hemostasis in all 
patients. Addit ional ly,  although the rate of reex- 
p lorat ion is low in this and other studies, careful 
preoperat ive analysis of risk for reexplorat ion may 
lower this rate further and improve outcome. 
In conclusion, we have demonstrated that four 
risk factors- -age,  renal insufficiency, procedure 
other than CABG,  and pro longed CPB t ime- -  
increase the risk of postoperat ive bleeding and 
reexploration. Reexplorat ion is a significant multi- 
variate predictor  of increased morbidity and mortal-  
ity in all patients, but specifically in a selected 
low-risk subgroup of patients. The amount of bleed- 
ing itself is probably the significant risk factor, and 
the decision to reexplore should be based on con- 
ventional  guidelines, because reexplorat ion does not 
likely affect the outcome after the fact. 
We gratefully acknowledge the assistance of Tina L. 
Burmeister and Patricia A. Locke-Buckley for data entry 
and retrieval. 
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Discussion 
Dr. Frederick L. Grover (Denver, Colo.). The purpose 
of this study, as mentioned, was to identify the preopera- 
tive risk factors that predispose to reexploration for 
bleeding and to examine the effect of reexploration for 
bleeding on postoperative outcomes. The authors hoped 
that by identifying those at highest risk for bleeding, 
interventions could be undertaken to decrease the likeli- 
hood of this event. They reviewed 6000 patients and 
"forced in" reexploration for bleeding (ordinarily an 
outcome variable) into their multivariate analysis, with 
preoperative and operative variables. We have also used 
this technique in both the Society of Thoracic Surgeons 
(STS) and the Veterans Administration (VA) databases. I 
believe it is permissible and leads to further information. 
For the purpose of this discussion I reviewed ata from 
the VA and the STS databases to see if these large 
databases could support your group's findings. From 1991 
to March of 1995, approximately 25,000 patients were 
entered into the VA database, with a 4.8% incidence of 
reexploration for bleeding. For those who underwent 
reexploration for bleeding, the risk of death was four 
times that of the average patient, even greater than the 
twofold increase in your study. There was also an in- 
creased incidence of mediastinitis, troke, renal failure, 
and prolonged mechanical ventilation. In this particular 
group of patients, the preoperative risk factors predictive 
for reoperation for bleeding were similar to yours: renal 
failure, prior heart surgery, emergency and urgent sur- 
gery, congestive heart failure, angina severity, age, and 
cardiac procedures other than CABG. 
The CABG-only data from the STS database for 1994 
were reviewed, and in this group there were 65,653 
patients with a 2.3% incidence of reexploration for bleed- 
ing. Those reoperated on for bleeding had an increased 
risk of operative mortality of 4.2 times that of those who 
did not have excessive bleeding; they also had an in- 
creased chance for prolonged ventilation, renal failure, 
septicemia, ARDS, stroke, deep sternal infection, and 
atrial fibrillation. Risk factors predictive for reoperation 
for bleeding were dialysis, steroids, cardiogenic shock, 
reoperation, emergency percutaneous transluminal coro- 
nary angioplasty within less than 6 hours, and several 
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other variables including aspirin, although the latter was 
not a major predictor, with an odds ratio of only 1.097. 
The data from these two large databases therefore 
support your findings of a significant increase in operative 
mortality and morbidity associated with reoperation for 
bleeding. They also identify many of the same factors that 
are predictive of patients likely to have this unfortunate 
event. 
I have a couple of questions. First, what are your 
criteria for reoperating on a patient for bleeding, and have 
you compared the outcomes of patients who are reoper- 
ated on relatively early versus later or who are in hemo- 
dynamically stable versus unstable condition? 
Dr. Moulton. There were eleven different surgeons who 
performed the operations in this study. These surgeons 
have slightly different criteria for returning to the opera- 
tion room for bleeding, although all of these surgeons 
followed conventional published guidelines in spirit. We 
analyzed our data in an attempt o determine if patients 
who were taken back early did better than those taken 
back late. we  divided the patients into groups on the basis 
of the amount of bleeding and looked at outcomes for 
patients who were returned to the operating room for 
bleeding and those who were not. We found that patients 
who had a small amount of bleeding and underwent 
reexploration actually did worse than those with a greater 
amount of bleeding. The reason is probably that patients 
with small amounts of Needing had serious complications, 
such as hemodynamic nstability or pericardial tampon- 
ade. 
Among the patients with greater amounts of bleeding, 
from 1500 to 2500 ml in the first 24 hours, those who 
underwent reexploration tended to do better than those 
who did not undergo reexploration. This observation 
possibly indicates that earlier reexploration would im- 
prove outcome. 
Dr. Grover. Now that you have identified a potentially 
high-risk group for this complication, are you intervening 
with aprotinin or other agents before the operation and 
have you had a chance to see if there has been any 
reduction in postoperative bleeding? 
Dr. Moulton. Aprotinin is being used only as an inves- 
tigational agent in our institution. Most of our surgeons 
still have reservations about its effects on graft patency 
and about the possibility that it contributes to the devel- 
opment of renal failure. 
As mentioned in the manuscript, we do believe that 
patients who were identified as being at high risk for 
bleeding-older patients with renal insufficiency undergo- 
ing procedures other than CABG and who are expected to 
have long CPB times--make up an excellent group on 
which to further investigate the efficacy of aprotinin. 
Over the past few years, one of our anesthesiologists 
has taken an interest in bleeding complications. Thus we 
have monitored heparin levels and measured prothrombin 
times and partial thromboplastin times on site. Since the 
institution of these measures, our incidence of bleeding 
complications has decreased. 
Dr. D. Craig Miller (Stanford, Calif.). Do you routinely 
use agents like aminocaproic acid (Amicar)? 
Dr. Moulton. We use agents like aminocaproic acid 
(Amicar) selectively. With the use of on-site heparin 
monitoring, we have reduced our need for other adjunc- 
tive agents to control bleeding. In most circumstances, we 
can determine the cause of the bleeding. In circumstances 
in which excessive fibrinolysis is implicated, we would use 
aminocaproic acid. 
Dr. Winfield J. Wells. (Los Angeles, Ca!if). Do your 
patients have a coagulation-related workup including such 
tests as prothrombin time, partial thromboplastin time, 
and bleeding time? If they do, could you draw any 
correlation between those tests and the incidence of 
bleeding? 
Dr. Moulton. We do obtain a prothrombin time, a 
partial thromboplastin time, a platelet count, and a bleed- 
ing time on all patients. These laboratory values have been 
a part of routine preoperative orders for some time. The 
bleeding time did not correlate with the amount of 
bleeding. 
Dr. Wells. On the basis of those findings, would you be 
willing to recommend that these tests be dropped from the 
preoperative workup in this age of increasing pressure 
from managed care to reduce costs? 
Dr. Moulton. I believe our data would support elimi- 
nating these tests. The only possible xception might be in 
patients with a history that suggests a tendency toward 
bleeding complications, such as patients with liver disease. 
Dr. John McDermott (Redding, Calif.). I understand 
that you are using the event of mediastinal reexploration 
as a marker for significant postoperative bleeding. Would 
it not be more accurate to express the concept that it is the 
bleeding itself, and the hemodynamic onsequences 
thereof, rather than the active reexploration, that has the 
effect on morbidity which your investigation defines. That 
is to say, would it not be more accurate to change the title 
and the viewpoint of the article to express the clinical fact 
that it is the hemodynamic effects of blood loss itself, the 
hemodynamic effects of even subtle or moderate medias- 
tinal accumulation on cardiac output and perfusion, espe- 
cially in those fragile or elderly patients with marginal or 
vulnerable cerebral or mesenteric perfusion, and the 
effects of blood product transfusion on the lungs and 
kidney which cumulatively produce the morbidity that you 
have observed? 
It would intuitively seem that mediastinal reexp!ora- 
tion is an ameliorating event in the bleeding patient. 
With that thought in mind, have you defined a differ- 
ence between those patients having early reexploration 
as compared with those patients who might have un- 
dergone exploration later or after more substantial 
hemodynamic consequences or more extensive blood 
product transfusion? 
A second question is whether you were able to define a 
group of patients who had not undergone reexploration 
but in retrospect had had substantial chest tube output. 
Does the outcome of those with substantial postoperative 
bleeding or substantial blood product transfusion differ 
from the outcome of the reexploration group or of the 
subpopulation that had early reexploration? 
Dr. Moulton. With respect to your first question, we had 
that same question too. What is the true variable that is 
causing the adverse outcome? We reran the analysis with 
"amount of bleeding ~' as the forced independent factor 
and essentially found the same results--not exactly the 
1 0 4 6 Moulton et aL 
The Journal of Thoracic and 
Cardiovascular Surgew 
May 1996 
same p values, but the same adverse outcomes were 
affected. Thus it appeared that amount of bleeding and 
the requirement of reexploration for bleeding were highly 
correlated and gav e us similar results. 
We also evaluated the patients who did not undergo 
reexploration, and the trend for the amount of bleeding to 
influence the outcome was less strong. As you suggest, 
hemodynamic instability and the requirement for multiple 
red cell transfusions are probably the factors that lead to 
renal failure, sepsis, ARDS, and ultimately increased 
operative mortality. 
Dr. McDermott. Your study spanned the years between 
1986 and 1993, that is, 7 years and more than 6000 
patients. During that time did you change your heparin or 
heparin/protamine protocol? If so, did you notice any 
change in the severity or extent of postoperative bleeding 
after changing to a more contemporary heparin/prota- 
mine protocol? 
Dr. Moulton. Yes, we did. On the basis of the intraop- 
erativ e assessment ofheparin levels in about 1991 or 1992, 
we did change our protocol. The rates of reexploration for 
bleeding subsequently declined over the study interval. 
